Biological Properties and Clinical Significance of Lipoprotein-Associated Phospholipase A2 in Ischemic Stroke
Ischemic stroke, which occurs following blockage of the blood supply to the brain, is a leading cause of death worldwide. Its main cause is atherosclerosis, a disease of the arteries characterized by the deposition of plaques of fatty material on the inner artery walls. Multiple proteins involved in...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Cardiovascular Therapeutics |
| Online Access: | http://dx.doi.org/10.1155/2022/3328574 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549727234686976 |
|---|---|
| author | Shuang Zhang Shuchun Huang Dingju Hu Fenglong Jiang Yanli Lv Guoqi Liu |
| author_facet | Shuang Zhang Shuchun Huang Dingju Hu Fenglong Jiang Yanli Lv Guoqi Liu |
| author_sort | Shuang Zhang |
| collection | DOAJ |
| description | Ischemic stroke, which occurs following blockage of the blood supply to the brain, is a leading cause of death worldwide. Its main cause is atherosclerosis, a disease of the arteries characterized by the deposition of plaques of fatty material on the inner artery walls. Multiple proteins involved in the inflammation response have been identified as diagnosing biomarkers of ischemic stroke. One of these is lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme that can hydrolyze circulating oxidized phospholipids, generating proinflammatory lysophosphatidylcholine and promoting the development of atherosclerosis. In the last two decades, a number of studies have revealed that both the concentration and the activity of Lp-PLA2 are independent biomarkers of ischemic stroke. The US Food and Drug Administration (FDA) has approved two tests to determine Lp-PLA2 mass and activity for predicting stroke. In this review, we summarize the biological properties of Lp-PLA2, the detection sensitivity and limitations of Lp-PLA2 measurement, the clinical significance and association of Lp-PLA2 in ischemic stroke, and the prospects of therapeutic inhibition of Lp-PLA2 as an intervention and treatment. |
| format | Article |
| id | doaj-art-84e110d2a6e34fe0ad8bc3b86f59b667 |
| institution | Kabale University |
| issn | 1755-5922 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiovascular Therapeutics |
| spelling | doaj-art-84e110d2a6e34fe0ad8bc3b86f59b6672025-02-03T06:08:43ZengWileyCardiovascular Therapeutics1755-59222022-01-01202210.1155/2022/3328574Biological Properties and Clinical Significance of Lipoprotein-Associated Phospholipase A2 in Ischemic StrokeShuang Zhang0Shuchun Huang1Dingju Hu2Fenglong Jiang3Yanli Lv4Guoqi Liu5Department of LaboratoryDepartment of NeurologyDepartment of NeurologyBiotecnovo (Beijing) Co. Ltd.Biotecnovo (Beijing) Co. Ltd.Biotecnovo (Beijing) Co. Ltd.Ischemic stroke, which occurs following blockage of the blood supply to the brain, is a leading cause of death worldwide. Its main cause is atherosclerosis, a disease of the arteries characterized by the deposition of plaques of fatty material on the inner artery walls. Multiple proteins involved in the inflammation response have been identified as diagnosing biomarkers of ischemic stroke. One of these is lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme that can hydrolyze circulating oxidized phospholipids, generating proinflammatory lysophosphatidylcholine and promoting the development of atherosclerosis. In the last two decades, a number of studies have revealed that both the concentration and the activity of Lp-PLA2 are independent biomarkers of ischemic stroke. The US Food and Drug Administration (FDA) has approved two tests to determine Lp-PLA2 mass and activity for predicting stroke. In this review, we summarize the biological properties of Lp-PLA2, the detection sensitivity and limitations of Lp-PLA2 measurement, the clinical significance and association of Lp-PLA2 in ischemic stroke, and the prospects of therapeutic inhibition of Lp-PLA2 as an intervention and treatment.http://dx.doi.org/10.1155/2022/3328574 |
| spellingShingle | Shuang Zhang Shuchun Huang Dingju Hu Fenglong Jiang Yanli Lv Guoqi Liu Biological Properties and Clinical Significance of Lipoprotein-Associated Phospholipase A2 in Ischemic Stroke Cardiovascular Therapeutics |
| title | Biological Properties and Clinical Significance of Lipoprotein-Associated Phospholipase A2 in Ischemic Stroke |
| title_full | Biological Properties and Clinical Significance of Lipoprotein-Associated Phospholipase A2 in Ischemic Stroke |
| title_fullStr | Biological Properties and Clinical Significance of Lipoprotein-Associated Phospholipase A2 in Ischemic Stroke |
| title_full_unstemmed | Biological Properties and Clinical Significance of Lipoprotein-Associated Phospholipase A2 in Ischemic Stroke |
| title_short | Biological Properties and Clinical Significance of Lipoprotein-Associated Phospholipase A2 in Ischemic Stroke |
| title_sort | biological properties and clinical significance of lipoprotein associated phospholipase a2 in ischemic stroke |
| url | http://dx.doi.org/10.1155/2022/3328574 |
| work_keys_str_mv | AT shuangzhang biologicalpropertiesandclinicalsignificanceoflipoproteinassociatedphospholipasea2inischemicstroke AT shuchunhuang biologicalpropertiesandclinicalsignificanceoflipoproteinassociatedphospholipasea2inischemicstroke AT dingjuhu biologicalpropertiesandclinicalsignificanceoflipoproteinassociatedphospholipasea2inischemicstroke AT fenglongjiang biologicalpropertiesandclinicalsignificanceoflipoproteinassociatedphospholipasea2inischemicstroke AT yanlilv biologicalpropertiesandclinicalsignificanceoflipoproteinassociatedphospholipasea2inischemicstroke AT guoqiliu biologicalpropertiesandclinicalsignificanceoflipoproteinassociatedphospholipasea2inischemicstroke |